Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
221-240 of 2,251 trials

Mantle-Cell Lymphoma: KTE-X19 CAR-T Cell Therapy

We are studying a new CAR-T cell therapy for patients with relapsed or refractory mantle-cell lymphoma who responded partially to ibrutinib. The trial aims to evaluate its effectiveness and safety in improving patient outcomes.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Propionic Acidemia: mRNA-3927 Treatment Study

We are investigating the safety and effectiveness of mRNA-3927 in individuals with propionic acidemia. The study aims to see if this treatment can reduce serious health events related to the condition.

Propionic AcidemiaSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyInternal Medicine

HPV Vaccination Timing After Stem Cell Transplant

We are comparing early versus late vaccination with Gardasil 9® in patients who have had a stem cell transplant. The goal is to see which timing produces a stronger immune response against HPV.

Recipients of Allogeneic Stem Cell TransplantationEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious DiseasesOncology

Eptinezumab for Migraines in Children and Adolescents

We are studying the long-term safety of eptinezumab in children and teens aged 6 to 17 who experience chronic or episodic migraines. This research aims to ensure the medication is safe for young patients.

Migraine6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Fronto-Temporal Dementia: LY3884963 Treatment Study

We are testing a new injection for patients with fronto-temporal dementia due to progranulin mutations. The study aims to evaluate its safety and effects on a key protein related to the disease.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Partial Lipodystrophy: Metreleptin Treatment Study

We are studying the daily use of metreleptin in patients with partial lipodystrophy to see if it improves their condition and related health factors. This includes looking at liver health and insulin sensitivity over time.

Partial Lipodystrophy>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Prostate Cancer: AAA617 Treatment Study

We are studying a new drug, AAA617, for adult men with oligometastatic prostate cancer to see if it can delay disease progression compared to standard observation. This trial aims to evaluate its effects on survival and quality of life.

Oligometastatic Prostate Cancer3-6 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Lung Cancer Treatment: DZD9008 vs. Chemotherapy

We are studying a new medication, DZD9008, for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if it works better than standard chemotherapy.

Advanced Non-Small Cell Lung Cancer with EGFR MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Severe Infections: MODIFY Trial

We are testing a new method to guide antibiotic treatment for severe infections, aiming to reduce unnecessary antibiotic use. This study will also evaluate how this approach impacts recovery and health outcomes.

Sepsis>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Atypical Hemolytic Uremic Syndrome: Long-Term Study of Iptacopan

We are evaluating the long-term safety and effects of iptacopan in individuals with atypical hemolytic uremic syndrome. This study looks at how well the treatment works in preventing complications and improving kidney health.

Atypical Hemolytic Uremic Syndrome>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

Filgotinib for Rare Immune Diseases

We are studying how filgotinib may improve quality of life and disease activity in patients with rare conditions like Behçet's disease, idiopathic inflammatory myopathy, and IgG4-related disease.

DermatomyositisAntisynthetase SyndromeIgG4-Related Disease6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesRheumatology

Cutibacterium acnes Infections: Rifampicin Study

We are investigating whether rifampicin is safe and effective for treating prosthetic joint infections caused by Cutibacterium acnes. This study compares rifampicin with other antibiotic treatments to see which works better.

Joint Infection from Medical Devices>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Metastatic Leiomyosarcoma: Lurbinectedin and Doxorubicin Study

We are investigating whether combining lurbinectedin with doxorubicin helps patients with metastatic leiomyosarcoma live longer without disease progression compared to doxorubicin alone. This study aims to improve treatment options for this rare cancer.

Metastatic Leiomyosarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Advanced Breast Cancer: Giredestrant vs. Fulvestrant

We are studying a new medication, giredestrant, to see if it works better than fulvestrant for patients with advanced breast cancer who have not responded to prior hormone therapy. The trial will also evaluate the safety of both treatments.

Estrogen Receptor Positive, HER2 Negative Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

ZN-c3 for High-Grade Serous Ovarian Cancer

We are studying a new treatment called azenosertib for individuals with high-grade serous ovarian cancer. The trial aims to evaluate its safety and effectiveness, especially in patients with a specific genetic marker.

Ovarian, Fallopian Tube, and Peritoneal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Atrial Fibrillation: Stopping Anticoagulants After Heart Surgery

We are studying whether patients with atrial fibrillation can safely stop anticoagulant therapy after undergoing surgical left atrial appendage closure. This trial looks at the risks of stroke and bleeding in these patients.

Atrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Early Breast Cancer: Ribociclib with Endocrine Therapy

We are studying the effects of ribociclib combined with endocrine therapy in patients with HR-positive, HER2-negative early breast cancer. This trial aims to understand how well this treatment works and its safety.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Flu Vaccine Study for Adults 65 and Older

We are testing a new adjuvanted flu vaccine to see if it works as well as a standard flu vaccine in preventing influenza in older adults. The study will also evaluate safety and immune response to the vaccine.

Influenza6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInfectious Diseases

Heart Failure Treatment: Carvedilol vs. Metoprolol

We are comparing two heart medications to see which one may better help patients with heart failure and reduced ejection fraction. This study involves patients who need beta-blocker treatment for their condition.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

TAK-330 for Reversing Blood Thinner Effects in Urgent Surgery

We are studying whether TAK-330 can effectively reverse the effects of certain blood thinners in patients needing urgent surgery. This trial compares TAK-330 to the standard treatment to see which works better.

Patients on Factor Xa Inhibitors Needing Urgent Intervention≤3 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine